• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Bionano Genomics Inc.

    4/2/26 4:04:43 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $BNGO alert in real time by email
    DEFA14A 1 bngo_defa_14a_naa_2026.htm DEFA14A DEFA14A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant  ☐

    Check the appropriate box:

     ☐

     

     

    Preliminary Proxy Statement

     ☐

     

     

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

     

     

    Definitive Proxy Statement

    ☒

     

     

    Definitive Additional Materials

     ☐

     

     

    Soliciting Material Pursuant to § 240.14a-12

     

    Bionano Genomics, Inc.

    (Name of Registrant as Specified in its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ☒

     

     

    No fee required.

     ☐

     

     

    Fee paid previously with preliminary materials.

     ☐

     

     

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     


     

    img93053740_0.jpg

     


     

     

    styleINAstyleINA P.O. BOX 8016, CARY, NC 27512-9903 Your vote matters! BIONANO GENOMICS, INC. Annual Meeting of Stockholders Thursday, May 14, 2026 10:00 AM, Pacific Time Annual meeting to be held via the internet - please visit www.proxydocs.com/BNGO You must register to attend the meeting online and/or participate at www.proxydocs.com/BNGO Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report on Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On May 14, 2026 For Stockholders of record as of March 19, 2026 To order paper materials, use one of the following methods. For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/BNGO To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before May 4, 2026. Internet: www.investorelections.com/BNGO Call: 1-866-648-8133 Email: [email protected] * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. SEE REVERSE FOR FULL AGENDA Copyright 2026 BetaNXT, Inc. or its affiliates. All Rights Reserved

     


     

    img93053740_1.jpg

     


     

    BIONANO GENOMICS, INC. Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ON PROPOSALS 1, 2 AND 3 PROPOSAL 1. Election of Class II Directors 1.01 Albert Luderer, Ph.D. 1.02 Kristiina Vuori, M.D., Ph.D. 2. To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement. 3. To ratify the selection of BDO USA, P.C. by the Audit Committee of the Board of Directors to serve as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

     

     


    Get the next $BNGO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BNGO

    DatePrice TargetRatingAnalyst
    11/15/2024Buy → Neutral
    Ladenburg Thalmann
    9/10/2024Buy → Neutral
    BTIG Research
    1/5/2023$4.00Sector Outperform
    Scotiabank
    12/12/2022$3.50Buy
    BTIG Research
    7/18/2022$12.00Outperform
    Oppenheimer
    More analyst ratings

    $BNGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF MEDICAL OFFICER Chaubey Alka covered exercise/tax liability with 18 shares, decreasing direct ownership by 3% to 644 units (SEC Form 4)

    4 - Bionano Genomics, Inc. (0001411690) (Issuer)

    2/18/26 4:31:45 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Principal Accounting Officer Adamchak Mark covered exercise/tax liability with 3 shares, decreasing direct ownership by 1% to 260 units (SEC Form 4)

    4 - Bionano Genomics, Inc. (0001411690) (Issuer)

    2/18/26 4:29:36 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    GENERAL COUNSEL Dixon Jonathan V. covered exercise/tax liability with 6 shares, decreasing direct ownership by 2% to 263 units (SEC Form 4)

    4 - Bionano Genomics, Inc. (0001411690) (Issuer)

    2/18/26 4:28:24 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BNGO
    SEC Filings

    View All

    SEC Form DEFA14A filed by Bionano Genomics Inc.

    DEFA14A - Bionano Genomics, Inc. (0001411690) (Filer)

    4/2/26 4:04:43 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form DEF 14A filed by Bionano Genomics Inc.

    DEF 14A - Bionano Genomics, Inc. (0001411690) (Filer)

    4/2/26 4:02:51 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form S-8 filed by Bionano Genomics Inc.

    S-8 - Bionano Genomics, Inc. (0001411690) (Filer)

    3/25/26 4:28:43 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BNGO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $BNGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bionano Reports Fourth Quarter and Full-Year 2025 Results and Provides Revenue Outlook for 2026

    SAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2025. "2025 demonstrated the momentum we built as a business," commented Erik Holmlin, PhD, president and CEO of Bionano. "Our routine users of optical genome mapping (OGM) and VIA™ software remain the foundation of our revenue and gross margins, and we are pleased to see continued growth in utilization among this core customer base. The global OGM community continues to show extraordinary energy, from the record attendance and engagement at the Bionano Symposium 2026 – where leading laboratories described scaling OGM w

    3/23/26 4:05:00 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bionano Announces Two-Fold Increase in OGM Studies Presented at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

    SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics (NASDAQ:BNGO) participated in the 2026 American College of Medical Genetics and Genomics Annual Meeting (ACMG), held March 14–18 in Baltimore, Maryland. Twelve studies, representing a two-fold increase over the number of studies in 2025, were presented as either oral (4) or poster presentations (8). The studies illustrated how optical genome mapping (OGM) can drive discoveries in genomics by detecting structural variants (SVs) that may be missed by other techniques across cancer genomics, such as hematologic malignancies, and constitutional genetic disorders, including rare diseases and reproductive disorders. Additionally, the

    3/17/26 8:00:00 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bionano to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call Webcast on March 23, 2026

    SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Monday, March 23, 2026, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and full year 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Monday, March 23rd, 2026Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:Registration – Click here Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at https://ir.biona

    3/9/26 4:05:00 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bionano Genomics downgraded by Ladenburg Thalmann

    Ladenburg Thalmann downgraded Bionano Genomics from Buy to Neutral

    11/15/24 7:40:01 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bionano Genomics downgraded by BTIG Research

    BTIG Research downgraded Bionano Genomics from Buy to Neutral

    9/10/24 7:37:53 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Scotiabank initiated coverage on Bionano Genomics with a new price target

    Scotiabank initiated coverage of Bionano Genomics with a rating of Sector Outperform and set a new price target of $4.00

    1/5/23 7:29:54 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BNGO
    Leadership Updates

    Live Leadership Updates

    View All

    Bionano Symposium 2026 Concluded with 9 Speakers Describing the Breadth of Bionano Solutions and Their Potential for Use on a Large Scale

    SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced highlights from the fourth and final day of Symposium 2026. Day 4 featured updates from some of the most advanced and high-volume cytogenetics and molecular pathology laboratories in the United States, Canada and Europe describing how they envision scaling optical genome mapping (OGM), including processing up to thousands of samples per year with automation, multiple OGM systems, and VIA™ software. Other talks covered topics like Bionano's Ionic® system for isolating DNA and RNA for next generation sequencing (NGS) and advanced analytical tools that could be the future of digital cytogenetics

    2/27/26 8:00:00 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    LeddarTech Appoints Chris Stewart as Chief Financial Officer

    QUEBEC CITY, Canada, Nov. 15, 2023 (GLOBE NEWSWIRE) -- LeddarTech®, an automotive software company that provides patented disruptive low-level sensor fusion and perception software technology for ADAS and AD, proudly announces the appointment of Mr. Chris Stewart as Chief Financial Officer ("CFO"). As CFO at LeddarTech, Mr. Stewart will be instrumental in supporting LeddarTech in completing its recently announced business combination with Prospector Capital Corp. and transitioning to a publicly traded company. Mr. Stewart has over 20 years of financial management experience at companies ranging from startups to large public companies. Mr. Stewart previously served as the Chief Financial

    11/15/23 12:07:00 AM ET
    $BNGO
    $PRSR
    $TSLA
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Blank Checks
    Finance

    Bionano Announces CFO Transition and Appointment of Gülsen Kama as Chief Financial Officer

    SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that Gülsen Kama will serve as its next Chief Financial Officer (CFO), effective September 11, 2023. Christopher Stewart, who held the position of CFO since September 2020, will stay on during the transition and then move into an advisory role. Ms. Kama has an extensive background in business planning and execution, especially in operating environments that demand rigorous management of expenses to enable profitable growth. She was most recently Chief Financial Officer at Northern Data AG, where she created and implemented a global finance organization to enable strong growth. Prior to Northe

    8/14/23 8:00:00 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BNGO
    Financials

    Live finance-specific insights

    View All

    Bionano Reports Fourth Quarter and Full-Year 2025 Results and Provides Revenue Outlook for 2026

    SAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2025. "2025 demonstrated the momentum we built as a business," commented Erik Holmlin, PhD, president and CEO of Bionano. "Our routine users of optical genome mapping (OGM) and VIA™ software remain the foundation of our revenue and gross margins, and we are pleased to see continued growth in utilization among this core customer base. The global OGM community continues to show extraordinary energy, from the record attendance and engagement at the Bionano Symposium 2026 – where leading laboratories described scaling OGM w

    3/23/26 4:05:00 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bionano to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call Webcast on March 23, 2026

    SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Monday, March 23, 2026, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and full year 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Monday, March 23rd, 2026Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:Registration – Click here Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at https://ir.biona

    3/9/26 4:05:00 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bionano to Report Third Quarter 2025 Financial Results and Host a Conference Call Webcast on November 13, 2025

    SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Thursday, November 13, 2025, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Thursday, November 13th, 2025Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:https://edge.media-server.com/mmc/p/4jh5a49o Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at htt

    10/30/25 4:05:00 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BNGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Bionano Genomics Inc. (Amendment)

    SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)

    2/13/24 5:00:51 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Bionano Genomics Inc. (Amendment)

    SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)

    7/7/23 4:35:55 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Bionano Genomics Inc. (Amendment)

    SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)

    1/30/23 4:03:23 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials